James Warden

James Warden — Patent Litigation Practice Summary

Specialty and side. Based on the tracked case data, James Warden's patent litigation work is entirely plaintiff-side and in-house: his single tracked appearance is as in-house counsel for plaintiff Optis Wireless Technology, LLC in Optis Wireless Technology, LLC et al. v. Apple Inc. (E.D. Tex.), a standard-essential patent / FRAND case over 4G/LTE wireless-communications technology. The available record therefore points to a focus on wireless/telecom standards litigation on behalf of a patent-assertion entity (the Optis/PanOptis family), rather than defending operating companies.

Firm context. Warden is in-house, not at a law firm. Public profile data (SignalHire) lists a James Warden as Chief Technology Officer at PanOptis — the parent of the Optis Wireless entities — with a long technical career at Motorola, BlackBerry, and Acacia Research and engineering degrees from the University of Texas at Arlington. That profile strongly suggests an engineer-turned-in-house technical/legal role with the Optis family, but it is an aggregator source and may describe a different individual; it cannot be used to confirm legal credentials, and I found no law-firm history or prior-firm affiliation tied to this name.

Notable case. The tracked matter, Optis v. Apple, is one of the more prominent SEP/FRAND cases of the last decade. In August 2021 an Eastern District of Texas jury awarded Optis roughly $300 million for Apple's FRAND breach, a verdict the Federal Circuit later vacated on damages grounds; on remand a 2023 retrial produced a substantially smaller award. I could not verify from the sources retrieved whether Warden personally appeared in the related PTAB/IPR proceedings over the asserted LTE patents, and I found no other verifiable verdicts or settlements naming him.

Bar and education. No bar admission or legal education could be verified from reliable sources; the technical-education and career details above come from an unverified professional-data aggregator and should be treated cautiously. PTAB/IPR activity for Warden personally is unconfirmed from the sources available.